Physician profile
Parag Patel
NPI 1114101128
$7,597.07
in general payments reported to CMS, 2019-2025
28 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what 76% of Nuclear Cardiology providers received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,402 · 2020: $1,106 · 2021: $529 · 2022: $413 · 2023: $738 · 2024: $1,343 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,147.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,221.56 | 2019-2025 | Triclip, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Boston Scientific Corporation | $1,931.31 | 2019-2025 | Watchman Flx |
| Pfizer INC. | $800.03 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $393.48 | 2021-2024 | Xarelto |
| Heartflow, INC. | $322.99 | 2022-2024 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $285.02 | 2020-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $210.12 | 2025 | |
| Lantheus Medical Imaging, INC. | $161.00 | 2019-2025 | Definity |
| Alnylam Pharmaceuticals INC. | $159.41 | 2022-2025 | Onpattro, Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $154.77 | 2023 | Camzyos |
| Novo Nordisk INC | $147.86 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $122.17 | 2021-2025 | Wainua, Farxiga, Lokelma |
| Kiniksa Pharmaceuticals International, Plc | $107.43 | 2024 | Arcalyst |
| Astellas Pharma US INC | $93.12 | 2019-2022 | |
| Philips North America LLC | $77.81 | 2024-2025 | Ecc Solutions, (Ck4) Mcot |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $64.81 | 2019-2024 | Repatha |
| Abiomed | $52.25 | 2019-2020 | |
| Edwards Lifesciences Corporation | $51.70 | 2022-2025 | Evoque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.42 | 2023-2025 | Jardiance |
| Kiniksa Pharmaceuticals, Ltd. | $33.46 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $26.91 | 2024 | Injectafer |
| Inspire Medical Systems, INC. | $22.77 | 2023 | Inspire |
| Bridgebio Pharma, INC. | $22.67 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $22.25 | 2021 | |
| Livanova USA, INC. | $19.43 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.56 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.18 | 2024 | |
| Novartis Pharmaceuticals Corporation | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parag Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.